IL18
ENSG00000150782
Target class
Secreted protein
Chromosome
11
Approved drugs
0
Clinical candidates (approved and in development)
3
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- IL18
- Gene name
- Interleukin 18
- Gene symbol
- IL18
- Protein name
- Interleukin-18 (IL-18) (Iboctadekin) (Interferon gamma-inducing factor) (IFN-gamma-inducing factor) (Interleukin-1 gamma) (IL-1 gamma)
- IGIF
- IL1F4
- IL-1g
- IL-18
- Gene biotype
- Protein coding
- Gene family
- Interleukins
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 51
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 169.06
- Tissue specificity (Gini)
- 0.694
- Tissue specificity (tau)
- 0.897
- KEGG gene identifiers
- hsa:3606
- Protein interaction confidence
- 0.843928
- Protein interaction partners
- 83
- R-HSA-448706
- R-HSA-5620971
- R-HSA-6783783
- R-HSA-6785807
- R-HSA-9012546
- R-HSA-9660826
- R-HSA-9960519
- R-HSA-9960525
- End position
- 112164106
- Start position
- 112143251
- Chromosome
- 11
- Strand
- Reverse
- Cytoplasm, cytosol . Secreted . Note=The precursor is cytosolic (PubMed:33883744). In response to inflammasome-activating signals, cleaved and secreted (PubMed:33883744, PubMed:37993712, PubMed:37993714). Mature form is secreted and released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33883744, PubMed:37993714). In contrast, the precursor form is not released, due to the presence of an acidic region that is proteolytically removed by CASP1, CASP4 or CASP5 during maturation (PubMed:33883744, PubMed:37993714). The secretion is dependent on protein unfolding and facilitated by the cargo receptor TMED10 (PubMed:32272059). .
- Cytosol
- Golgi apparatus
- PubMed 32272059
- PubMed 33883744
- PubMed 9334240
- PubMed 23955712
- PubMed 37993712
- PubMed 37993714
- Tissue specificity (tau)
- 0.896735
- Expression inequality (Gini)
- 0.693568
Expression in transcripts per million
- Skin - Sun Exposed (Lower leg)
- 169.06
- Skin - Not Sun Exposed (Suprapubic)
- 164.8
- Esophagus - Mucosa
- 132.08
- Vagina
- 113.83
- Spleen
- 58
Expression in transcripts per million
- Skin - Sun Exposed (Lower leg)169.06
- Skin - Not Sun Exposed (Suprapubic)164.8
- Esophagus - Mucosa132.08
- Vagina113.83
- Spleen58
- Nerve - Tibial39.31
- Lung36.26
- Small Intestine - Terminal Ileum32.02
- Adipose - Visceral (Omentum)30.46
- Colon - Transverse30.01
- Kidney - Cortex27.54
- Kidney - Medulla22.46
- Bladder18.61
- Brain - Spinal cord (cervical c-1)15.8
- Prostate13.27
- Minor Salivary Gland12.05
- Adipose - Subcutaneous9.82
- Whole Blood9.79
- Artery - Coronary8.94
- Fallopian Tube8.49
- Esophagus - Gastroesophageal Junction8.46
- Stomach8.27
- Artery - Aorta8.2
- Esophagus - Muscularis7.35
- Adrenal Gland7.11
And 29 more, listed on the interactive page.
- GO:0001525
- GO:0007267
- GO:0030155
- GO:0032722
- GO:0032725
- GO:0032729
- GO:0032736
- GO:0032740
- GO:0032819
- GO:0034105
- GO:0035655
- GO:0042088
- GO:0042092
- GO:0042104
- GO:0042531
- GO:0045944
- GO:0048661
- GO:0050729
- GO:0051142
- GO:0051897
- GO:0150078
- GO:2000556
- GO:0005576
- GO:0005829
- GO:0005125
- GO:0005515
- GO:0045515
Related records
Trials (9)
- A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
- A Study to Evaluate Camoteskimab in Participants With Still's Disease
- A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease
- Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
- Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
- Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease
- Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency
- Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension
Drugs (3)
- Camoteskimab Interleukin-18 cross-linking agent
- GSK-1070806 Interleukin-18 inhibitor
- Tadekinig alfa Interleukin-18 inhibitor